-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
BTK inhibitors have become a promising drug in the hematology market and a popular target for autoimmune disorders due to their various advantages
.
According to relevant data analysis, the global market for BTK inhibitors is growing rapidly and is expected to reach US$11.
5 billion in 2022; by 2025, the market size is expected to reach US$20 billion; in 2030, it may grow to US$26.
1 billion
.
With the continuous expansion of the market, pharmaceutical companies are also stepping up their layout
.
Among them, the pharmaceutical companies that entered the bureau first achieved greater advantages
.
For example, according to relevant statistics, in 2021, the global sales revenue of ibrutinib will be nearly 9.
7 billion US dollars, the sales of acaltinib will exceed 1.
2 billion US dollars, and the sales of zanubrutinib will exceed 200 million US dollars
.
The data shows that the domestic BTK inhibitor market for the treatment of B-cell lymphoma is also rapidly expanding.
In 2020, the market size will reach 1.
3 billion yuan, and it is expected to grow to 13.
1 billion yuan in 2025; it may reach 22.
5 billion yuan in 2030.
Yuan
.
Facing the broad market demand, domestic enterprises also stepped up to enter the market
.
Among them, BeiGene and Nuocheng Jianhua applied for listing on the front and rear legs, and the drug research and development of Hengrui Medicine and Hezheng Medicine has entered the clinical stage
.
At the same time, 9 domestic pharmaceutical companies, including Chia Tai Tianqing and Hisun Pharmaceutical, are developing generic drugs of ibrutinib.
Simcere Pharmaceuticals has applied for listing, Hangzhou Zhongmei Huadong Pharmaceutical has entered the BE trial stage, Chia Tai Tianqing, Haizheng Pharmaceutical Co.
, Ltd.
Zheng Pharmaceutical, Shanghai Huilun, etc.
have approved clinical trials and are conducting clinical research
.
It is reported that there are currently three BTK inhibitors approved for marketing in China, and all of them have been included in the medical insurance
.
The three BTK inhibitors are Janssen (Johnson & Johnson)'s ibrutinib, BeiGene's zanubrutinib, and Nuocheng Jianhua's orbrutinib
.
Ibrutinib has many approved indications, including second-line and first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), second-line treatment of mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM) Second-line therapy
.
In 2018, ibrutinib entered the medical insurance catalog; in December 2020, zanubrutinib was approved for the second-line treatment of MCL and CLL/SLL with two conditional indications and entered the medical insurance, and it will take effect in March 2021
.
In December 2021, zanubrutinib added the second-line treatment of WM into the medical insurance catalog, and two indications of orelabrutinib for MCL and CLL/SLL were also included in the medical insurance catalog
.
Among them, Orbrutinib and Zanubrutinib are stepping up the expansion of new indications to seek a larger market share
.
Take Nuocheng Jianhua's orelabrutinib as an example, which was approved in China on December 25, 2020 for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and Two indications for relapsed/refractory mantle cell lymphoma (MCL)
.
On March 14, 2022, Nuocheng Jianhua announced that the NMPA Center for Drug Evaluation has accepted its BTK inhibitor orelabrutinib for the treatment of patients with relapsed/refractory Waldenström's macroglobulinemia
.
Analysts said that there is still a lot of room for growth in the sales of domestic drugs on the BTK inhibitor track
.
Even though ibrutinib still has the right to speak, there are less than 5 years left until the patent expires.
In the future, with the intensified research and development of local pharmaceutical companies and the launch of products, the market pattern of domestic BTK inhibitors will occur.
new changes
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to relevant data analysis, the global market for BTK inhibitors is growing rapidly and is expected to reach US$11.
5 billion in 2022; by 2025, the market size is expected to reach US$20 billion; in 2030, it may grow to US$26.
1 billion
.
With the continuous expansion of the market, pharmaceutical companies are also stepping up their layout
.
Among them, the pharmaceutical companies that entered the bureau first achieved greater advantages
.
For example, according to relevant statistics, in 2021, the global sales revenue of ibrutinib will be nearly 9.
7 billion US dollars, the sales of acaltinib will exceed 1.
2 billion US dollars, and the sales of zanubrutinib will exceed 200 million US dollars
.
The data shows that the domestic BTK inhibitor market for the treatment of B-cell lymphoma is also rapidly expanding.
In 2020, the market size will reach 1.
3 billion yuan, and it is expected to grow to 13.
1 billion yuan in 2025; it may reach 22.
5 billion yuan in 2030.
Yuan
.
Facing the broad market demand, domestic enterprises also stepped up to enter the market
.
Among them, BeiGene and Nuocheng Jianhua applied for listing on the front and rear legs, and the drug research and development of Hengrui Medicine and Hezheng Medicine has entered the clinical stage
.
At the same time, 9 domestic pharmaceutical companies, including Chia Tai Tianqing and Hisun Pharmaceutical, are developing generic drugs of ibrutinib.
Simcere Pharmaceuticals has applied for listing, Hangzhou Zhongmei Huadong Pharmaceutical has entered the BE trial stage, Chia Tai Tianqing, Haizheng Pharmaceutical Co.
, Ltd.
Zheng Pharmaceutical, Shanghai Huilun, etc.
have approved clinical trials and are conducting clinical research
.
It is reported that there are currently three BTK inhibitors approved for marketing in China, and all of them have been included in the medical insurance
.
The three BTK inhibitors are Janssen (Johnson & Johnson)'s ibrutinib, BeiGene's zanubrutinib, and Nuocheng Jianhua's orbrutinib
.
Ibrutinib has many approved indications, including second-line and first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), second-line treatment of mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM) Second-line therapy
.
In 2018, ibrutinib entered the medical insurance catalog; in December 2020, zanubrutinib was approved for the second-line treatment of MCL and CLL/SLL with two conditional indications and entered the medical insurance, and it will take effect in March 2021
.
In December 2021, zanubrutinib added the second-line treatment of WM into the medical insurance catalog, and two indications of orelabrutinib for MCL and CLL/SLL were also included in the medical insurance catalog
.
Among them, Orbrutinib and Zanubrutinib are stepping up the expansion of new indications to seek a larger market share
.
Take Nuocheng Jianhua's orelabrutinib as an example, which was approved in China on December 25, 2020 for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and Two indications for relapsed/refractory mantle cell lymphoma (MCL)
.
On March 14, 2022, Nuocheng Jianhua announced that the NMPA Center for Drug Evaluation has accepted its BTK inhibitor orelabrutinib for the treatment of patients with relapsed/refractory Waldenström's macroglobulinemia
.
Analysts said that there is still a lot of room for growth in the sales of domestic drugs on the BTK inhibitor track
.
Even though ibrutinib still has the right to speak, there are less than 5 years left until the patent expires.
In the future, with the intensified research and development of local pharmaceutical companies and the launch of products, the market pattern of domestic BTK inhibitors will occur.
new changes
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
